Early Results For Therapyx/Intravacc's Vaccine May Herald Progress In Gonorrhea Prevention
SBIR Award Received From The US NIAID
Executive Summary
Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.
You may also be interested in...
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Double-Action Antibiotic Advances In GSK's Pipeline
GlaxoSmithKline has initiated Phase III studies, EAGLE-1 and EAGLE-2, of potentially a new chemical class of oral antibiotic in patients with infections of public health concern, gonorrhea and urinary tract infections.
Peptomyc Tackling ‘Undruggable’ Myc For Anticancers
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.
Need a specific report? 1000+ reports available
Buy Reports